A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CVM SEC filings page.
This page shows Cel-Sci Corporation (CVM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Losses are narrowing, but operating cash remains negative and the business still relies on financing inflows.
The operating loss narrowed from$36.4M in FY2021 to$24.8M in FY2025, yet operating cash flow remained negative at-$17.1M in FY2025. That combination indicates improving reported performance has not yet translated into self-funded operations; FY2025 financing cash flow of$23.4M supplied the offset.
The balance sheet has been compressed: total assets fell from
Spending has become more selective: research and development was
Financial Health Signals
We do not publish a peer-relative financial health score for Cel-Sci Corporation, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Cel-Sci Corporation passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Cel-Sci Corporation reported a net loss of $25.4M while operations used $17.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Cel-Sci Corporation reported an operating loss of $24.8M against $649K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cel-Sci Corporation's EBITDA was -$4.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cel-Sci Corporation reported a net loss of $5.7M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Cel-Sci Corporation recorded an outflow of $4.0M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cel-Sci Corporation held $6.5M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Cel-Sci Corporation's quarterly ROE was -51.7% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 28.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 27.8 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Cel-Sci Corporation invested $3.6M in research and development in Q3 2026. This represents a decrease of 2.4% from the same quarter a year earlier. Against the prior quarter it is down 3.1%.
Cel-Sci Corporation reported no capital expenditure in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
CVM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $3.6M-2.4% | $3.8M-6.2% | $3.7M-17.0% | $3.7M-17.3% | $3.7M-20.5% | $4.0M-13.3% | $4.4M+1.8% | $4.5M-15.0% |
| SG&A Expenses | $1.9M+9.1% | $1.6M-34.5% | $1.7M-31.3% | $2.3M+41.8% | $1.7M-11.1% | $2.4M-2.8% | $2.5M+15.5% | $1.6M-25.3% |
| Operating Income | -$5.6Mn/m | -$5.3Mn/m | -$5.4Mn/m | -$6.0Mn/m | -$5.5Mn/m | -$6.4Mn/m | -$6.9Mn/m | -$6.1Mn/m |
| EBITDA | -$4.6Mn/m | -$4.4Mn/m | -$4.4Mn/m | -$5.1Mn/m | -$4.5Mn/m | -$5.4Mn/m | -$5.9Mn/m | -$5.1Mn/m |
| Interest Expense | $111K-35.5% | $117K-34.3% | $88K-48.2% | $129K | $172K | $178K | $170K | N/A |
| Net Income | -$5.7Mn/m | -$5.5Mn/m | -$5.5Mn/m | -$6.1M | -$5.7Mn/m | -$6.6Mn/m | -$7.1Mn/m | N/A |
| EPS (Diluted) | -$0.47 | -$0.67 | -$0.68 | $0.07 | -$1.36 | -$2.33 | -$3.25n/m | -$2.80 |
| Diluted Shares (Avg) | 12M | 8M | 8M | N/A | 4M | 3M | 2M+34.8% | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax, EPS (Basic).
CVM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'25Filing | Q1'25Filing | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $21.4M+5.0% | $17.7M-18.8% | $22.9M-10.9% | $28.2M+4.3% | $20.3M-15.5% | $21.8M-27.4% | $25.7M-10.5% | $27.0M-11.6% |
| Current Assets | $7.5M+186.1% | $2.9M-4.3% | $7.0M+20.0% | $11.6M+91.5% | $2.6M-26.0% | $3.0M-64.5% | $5.9M-4.8% | $6.1M-12.5% |
| Cash & Equivalents | $6.5M+264.1% | $1.9M-1.7% | $6.3M+36.1% | $11.0M+131.2% | $1.8M+366.1% | $1.9M-63.8% | $4.6M+42.3% | $4.7M+14.3% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.0M-54.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $10.4M-21.9% | $10.8M-21.6% | $11.8M-18.3% | $12.2M-13.6% | $13.3M-14.6% | $13.8M-12.3% | $14.4M-10.4% | $14.1M-18.4% |
| Current Liabilities | $5.1M-9.6% | $4.8M-12.6% | $5.0M-8.0% | $5.1M+11.2% | $5.6M+2.0% | $5.5M+8.1% | $5.5M+12.6% | $4.6M-17.4% |
| Non-Current Liabilities | $5.3M-30.9% | $6.0M-27.5% | $6.7M-24.6% | $7.1M-25.7% | $7.7M-23.7% | $8.3M-22.0% | $8.9M-20.4% | $9.5M-18.9% |
| Long-Term Debt | N/A | N/A | N/A | $5.7M | N/A | N/A | N/A | N/A |
| Total Equity | $11.0M+56.0% | $6.9M-14.0% | $11.1M-1.5% | $16.0M+24.0% | $7.0M-17.1% | $8.0M-44.1% | $11.3M-10.6% | $12.9M-2.6% |
| Retained Earnings | -$556.0Mn/m | -$550.4Mn/m | -$544.9Mn/m | -$539.4Mn/m | -$533.3Mn/m | -$527.7Mn/m | -$521.1Mn/m | -$514.0Mn/m |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.
CVM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.0Mn/m | -$4.0Mn/m | -$4.0Mn/m | -$4.7Mn/m | -$3.9Mn/m | -$4.4Mn/m | -$4.1Mn/m | -$4.8Mn/m |
| Depreciation & Amortization | $946K-1.3% | $956K-1.4% | $964K-3.1% | $961K-3.1% | $959K-2.6% | $970K-1.9% | $995K-0.9% | $992K-0.7% |
| Stock-Based Compensation | N/A | N/A | $443K-37.7% | N/A | N/A | N/A | $711K-48.6% | N/A |
| Capital Expenditures | $0n/m | $0n/m | $0-100.0% | $5K-73.9% | $0-100.0% | $0n/m | $33K-36.2% | $20Kn/m |
| Free Cash Flow | -$4.0Mn/m | -$4.0Mn/m | -$4.0Mn/m | -$4.7Mn/m | -$3.9Mn/m | -$4.4Mn/m | -$4.2Mn/m | -$4.8Mn/m |
| Investing Cash Flow | $0n/m | $0n/m | $0n/m | -$5Kn/m | $0n/m | $0n/m | -$33Kn/m | -$20Kn/m |
| Financing Cash Flow | $8.7M+127.6% | -$364K-121.7% | -$654K-116.1% | $13.8M+50.6% | $3.8Mn/m | $1.7M-74.5% | $4.0M0.0% | $9.2M+126.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CVM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -51.7%+28.9pp | -79.5%+2.7pp | -49.1%+13.4pp | -38.2% | -80.6%+0.3pp | -82.2%-31.5pp | -62.5%-9.5pp | N/A |
| Return on Assets | -26.5%+1.3pp | -30.9%-0.7pp | -23.9%+3.6pp | -21.7% | -27.9%+0.6pp | -30.1%-6.0pp | -27.5%-4.2pp | N/A |
| Current Ratio | 1.48+1.0x | 0.60+0.1x | 1.39+0.3x | 2.26+0.9x | 0.47-0.2x | 0.55-1.1x | 1.07-0.2x | 1.31+0.1x |
| Debt-to-Equity | N/A | N/A | N/A | 0.36 | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 0.95-0.9x | 1.58-0.2x | 1.06-0.2x | 0.76-0.3x | 1.89+0.1x | 1.73+0.6x | 1.270.0x | 1.10-0.2x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Cel-Sci Corporation CVM | FY2025 | N/A | -$25.4M | N/A | $21.3M | — |
| BeyondSpring Inc. BYSI | FY2025 | $0 | -$1.0M | N/A | $13.7M | — |
| TransCode Therapeutics, Inc. RNAZ | FY2025 | N/A | -$34.7M | N/A | $20.1M | — |
| Edesa Biotech, Inc. EDSA | FY2025 | N/A | -$7.2M | N/A | $27.0M | — |
| ABVC BioPharma, Inc. ABVC | FY2025 | $296K | -$7.9M | N/A | $23.4M | — |
| Estrella Immunopharma, Inc. ESLA | FY2025 | N/A | -$13.1M | N/A | $14.1M | — |
Where Cel-Sci Corporation Ranks
Frequently Asked Questions
No, Cel-Sci Corporation (CVM) reported a net loss of $22.7M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $25.4M.
Cel-Sci Corporation (CVM) had EBITDA of -$22.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Cel-Sci Corporation (CVM) had $11.0M in cash and equivalents against $5.7M in long-term debt.
Cel-Sci Corporation (CVM) has a return on equity of -159.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Cel-Sci Corporation (CVM) recorded an outflow of $17.2M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Cel-Sci Corporation (CVM) recorded an outflow of $17.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Cel-Sci Corporation (CVM) had $28.2M in total assets as of fiscal year 2025, including both current and long-term assets.
Cel-Sci Corporation (CVM) invested $38K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Cel-Sci Corporation (CVM) invested $15.9M in research and development during fiscal year 2025.
Cel-Sci Corporation (CVM) had a current ratio of 2.26 as of fiscal year 2025, which is generally considered healthy.
Cel-Sci Corporation (CVM) had a debt-to-equity ratio of 0.36 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Cel-Sci Corporation (CVM) had a liabilities-to-equity ratio of 0.76 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Cel-Sci Corporation (CVM) had a return on assets of -90.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Cel-Sci Corporation (CVM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $21.3M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Cel-Sci Corporation (CVM) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $21.3M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Cel-Sci Corporation (CVM) held $11.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $17.1M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Cel-Sci Corporation (CVM) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Cel-Sci Corporation (CVM) reported a net loss of $25.4M while operations used $17.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Cel-Sci Corporation (CVM) reported an operating loss of $24.8M against $649K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.